『Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals』のカバーアート

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

著者： Fexingo
無料で聴く

Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure? #Biotech #Lifesciences #DrugDiscovery #FDAApprovals #ClinicalTrials #Startups #VentureCapital #Pharma #Genomics #CRISPR #Therapeutics #RegulatoryScience #Patents #Investment #Business #FexingoBusiness #BusinessPodcast #Technology Keep every episode free: buymeacoffee.com/fexingo© 2026 Fexingo. All rights reserved. 経済学
エピソード
  • How Biotech Startups Are Using Base Editing to Treat Genetic Disease

    How Biotech Startups Are Using Base Editing to Treat Genetic Disease
    2026/06/07
    Base editing is a newer gene-editing technology that can change a single DNA letter without cutting the double helix. In this episode, Lucas and Luna explore how biotech startups are applying base editing to treat genetic diseases like sickle cell disease and progeria. They discuss the story of Beam Therapeutics, the first company to take a base editor into clinical trials, and contrast base editing with both traditional CRISPR and newer prime editing. The hosts break down the science behind adenine and cytosine base editors, the business of licensing foundational IP from the Broad Institute, and the regulatory path for in vivo therapies. They also touch on the ethical considerations and what this means for patients with currently untreatable conditions. Specific numbers: Beam's lead program in sickle cell disease, the estimated patient population, and the timeline for early-phase data. This episode is for anyone interested in the frontier of precision genetic medicine beyond CRISPR-Cas9. #BaseEditing #GeneEditing #BeamTherapeutics #SickleCellDisease #Progeria #DavidLiu #BroadInstitute #PrimeEditing #CRISPR #PrecisionMedicine #GeneticDisease #AdenineBaseEditor #CytosineBaseEditor #BiotechStartups #FDA #ClinicalTrials #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    9 分
  • How Biotech Startups Are Using Liquid Biopsies for Early Cancer Detection

    How Biotech Startups Are Using Liquid Biopsies for Early Cancer Detection
    2026/06/06
    Episode 35 of Biotech Business with Fexingo dives into the world of liquid biopsies — blood tests that detect tumor DNA before symptoms appear. Lucas and Luna discuss how startups like Guardant Health and Grail are driving this technology, the science of circulating tumor DNA, and why regulatory shifts in 2026 are accelerating adoption. They also explore the economics: how liquid biopsies could cut screening costs by 60% and what that means for insurers. A compelling look at a field that's reshaping oncology from the ground up. #LiquidBiopsy #CancerDetection #GuardantHealth #Grail #CirculatingTumorDNA #EarlyCancerDetection #Oncology #BiotechStartups #FDAApprovals #PrecisionMedicine #LungCancer #ColorectalCancer #Diagnostics #BloodTest #Genomics #HealthcareInnovation #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    11 分
  • How Biotech Startups Use Antibody Drug Conjugates to Treat Cancer

    How Biotech Startups Use Antibody Drug Conjugates to Treat Cancer
    2026/06/06
    In this episode, Lucas and Luna explore the science and business behind antibody-drug conjugates (ADCs), a targeted cancer therapy that combines monoclonal antibodies with potent chemotherapy. They unpack the case of Enhertu, an ADC developed by Daiichi Sankyo and AstraZeneca, which has shown remarkable efficacy in HER2-positive cancers. The hosts discuss how ADCs work like 'guided missiles' for cancer cells, the engineering challenges of linker technology, and the deal-making landscape around ADCs. They also highlight the growing interest from big pharma in ADC platforms, with more than 100 ADCs in clinical trials as of mid-2026. Lucas shares data on the ADC market, projected to exceed $30 billion by 2030, while Luna questions whether these therapies can overcome toxicity limitations. The episode ties in the broader trend of biologics and targeted drug delivery, offering listeners a concrete understanding of a technology that is reshaping oncology treatment. #AntibodyDrugConjugates #ADC #CancerTherapy #Oncology #Biotech #DrugDiscovery #TargetedTherapy #Enhertu #DaiichiSankyo #AstraZeneca #MonoclonalAntibodies #LinkerTechnology #Payload #HER2 #Business #Technology #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    12 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません